BioCentury
ARTICLE | Clinical News

FDA panel backs volanesorsen approval

May 11, 2018 6:15 PM UTC

FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 12-8 to approve Waylivra volanesorsen from Akcea Therapeutics Inc. (NASDAQ:AKCA) to treat familial chylomicronemia syndrome, a rare lipid disorder that results from lipoprotein lipase deficiency.

The company is developing the antisense inhibitor of apolipoprotein C-III (APOCIII; APOC3) with Ionis Pharmaceuticals Inc. (NASDAQ:IONS)...